Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G et al (2017) Global, Regional, and National Burden of Cardiovascular Diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol 70(1):1–25
Article PubMed PubMed Central Google Scholar
Bonaca MP, Braunwald E, Sabatine MS (2015) Long-term use of Ticagrelor in patients with prior Myocardial Infarction. N Engl J Med 373(13):1274–1275
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361(11):1045–1057
Article CAS PubMed Google Scholar
Van Giezen JJJ, Nilsson L, Berntsson P, Wissing B-M, Giordanetto F, Tomlinson W et al (2009) Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 7(9):1556–1565
Bae JP, Dobesh PP, Klepser DG, Anderson JD, Zagar AJ, McCollam PL et al (2012) Adherence and dosing frequency of common medications for cardiovascular patients. Am J Manag Care 18(3):139–146
Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC (2009) Effect of medication dosing frequency on adherence in chronic Diseases. Am J Manag Care 15(6):e22–33
Huber CA, Meyer MR, Steffel J, Blozik E, Reich O, Rosemann T (2019) Post-myocardial infarction (MI) care: Medication Adherence for secondary Prevention after MI in a large real-world Population. Clin Ther 41(1):107–117
Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B et al (2013) Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 382(9906):1714–1722
Rasmussen JN, Chong A, Alter DA (2007) Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute Myocardial Infarction. JAMA 297(2):177–186
Article CAS PubMed Google Scholar
Bingham JM, Black M, Anderson EJ, Li Y, Toselli N, Fox S et al (2021) Impact of Telehealth interventions on Medication Adherence for patients with type 2 Diabetes, Hypertension, and/or dyslipidemia: a systematic review. Ann Pharmacother 55(5):637–649
Chan MY, Koh KWL, Poh S-C, Marchesseau S, Singh D, Han Y et al (2021) Remote Postdischarge treatment of patients with Acute Myocardial Infarction by Allied Health Care Practitioners vs Standard Care: the IMMACULATE Randomized Clinical Trial. JAMA Cardiol 6(7):830–835
Ho PM, Lambert-Kerzner A, Carey EP, Fahdi IE, Bryson CL, Melnyk SD et al (2014) Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. JAMA Intern Med 174(2):186–193
Kubica A, Kasprzak M, Obonska K, Fabiszak T, Laskowska E, Navarese EP et al (2015) Discrepancies in assessment of adherence to antiplatelet treatment after Myocardial Infarction. Pharmacology 95(1–2):50–58
Article CAS PubMed Google Scholar
Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schömig A et al (2009) Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent Thrombosis. J Am Coll Cardiol 53(10):849–856
Article CAS PubMed Google Scholar
Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R et al (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56(12):919–933
Article CAS PubMed Google Scholar
Ndrepepa G, Schuster T, Hadamitzky M, Byrne RA, Mehilli J, Neumann FJ et al (2012) Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery Disease undergoing percutaneous coronary intervention. Circulation 125(11):1424–1431
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD et al (2012) Third universal definition of Myocardial Infarction. J Am Coll Cardiol 60(16):1581–1598
Chow CK, Klimis H, Thiagalingam A, Redfern J, Hillis GS, Brieger D et al (2022) Text messages to improve Medication Adherence and secondary Prevention after Acute Coronary Syndrome: the TEXTMEDS Randomized Clinical Trial. Circulation 145(19):1443–1455
Schwalm JD, Ivers NM, Natarajan MK, Taljaard M, Rao-Melacini P, Witteman HO et al (2015) Cluster randomized controlled trial of delayed Educational Reminders for Long-Term Medication Adherence in ST-Elevation Myocardial Infarction (DERLA-STEMI). Am Heart J 170(5):903–913
Calvert SB, Kramer JM, Anstrom KJ, Kaltenbach LA, Stafford JA, Allen LaPointe NM (2012) Patient-focused intervention to improve long-term adherence to evidence-based medications: a randomized trial. Am Heart J 163(4):657–665 e1
Parsons HM (1974) What happened at Hawthorne? New evidence suggests the Hawthorne effect resulted from operant reinforcement contingencies. Science 183(4128):922–932
Article CAS PubMed Google Scholar
Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353(5):487–497
Article CAS PubMed Google Scholar
Marcum ZA, Sevick MA, Handler SM (2013) Medication nonadherence: a diagnosable and treatable medical condition. JAMA 309(20):2105–2106
Article CAS PubMed PubMed Central Google Scholar
Arora S, Shemisa K, Vaduganathan M, Qamar A, Gupta A, Garg SK et al (2019) Premature Ticagrelor discontinuation in Secondary Prevention of Atherosclerotic CVD: JACC Review topic of the Week. J Am Coll Cardiol 73(19):2454–2464
Article CAS PubMed Google Scholar
Bonaca MP, Bhatt DL, Oude Ophuis T, Steg PG, Storey R, Cohen M et al (2016) Long-term tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: a secondary analysis of the PEGASUS-TIMI 54 Trial. JAMA Cardiol 1(4):425–432
Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM et al (2022) 2021 ACC/AHA/SCAI Guideline for Coronary Artery revascularization: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice guidelines. Circulation 145(3):e4–e17
Collet JP, Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt DL et al (2021) 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Rev Esp Cardiol (Engl Ed) 74(6):544
Pietrzykowski L, Michalski P, Kosobucka A, Kasprzak M, Fabiszak T, Stolarek W et al (2020) Medication adherence and its determinants in patients after Myocardial Infarction. Sci Rep 10(1):12028
Article CAS PubMed PubMed Central Google Scholar
Thim T, Johansen MB, Chisholm GE, Schmidt M, Kaltoft A, Sørensen HT et al (2014) Clopidogrel discontinuation within the first year after coronary drug-eluting stent implantation: an observational study. BMC Cardiovasc Disord 14:100
Article PubMed PubMed Central Google Scholar
Latry P, Martin-Latry K, Lafitte M, Peter C, Couffinhal T (2012) Dual antiplatelet therapy after Myocardial Infarction and percutaneous coronary intervention: analysis of patient adherence using a French health insurance reimbursement database. EuroIntervention: journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. 7(12):1413–1419
Lauffenburger JC, Choudhry NK (2018) A call for a systems-thinking Approach to Medication Adherence: stop blaming the patient. JAMA Intern Med 178(7):950–951
Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC et al (2012) Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol 60(3):193–199
Article CAS PubMed Google Scholar
Alexopoulos D, Xanthopoulou I, Stavrou K, Hahalis G, Davlouros P (2013) Platelet reactivity measurements reveal patient noncompliance during ticagrelor maintenance therapy. Can J Cardiol 29(12):1743e13–1743e14
Comments (0)